Advancing a class on top of statins
Investors & Media

RSS Content

Gemphire to Present at the LD Micro Invitational and the Jefferies 2017 Global Healthcare Conference

LIVONIA, Mich., June 01, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced that management will provide a corporate update at LD Micro Invitational, taking place June 6-7 in Los Angeles, California, and at the Jefferies 2017 Global Healthcare Conference, taking place June 6-9, 2017, in New York City.

LD Micro Invitational
Date:     Tuesday, June 6th
Time:      4:00 pm Pacific Time
Presenter:     Charles Bisgaier, Ph.D., Chief Scientific Officer
Location:     Luxe Sunset Boulevard Hotel, Los Angeles, CA
       
Jefferies 2017 Global Healthcare Conference
Date:     Thursday, June 8th
Time:     4:00pm Eastern Time
Presenter:     Lee Golden, MD, Chief Medical Officer
Location:     Grand Hyatt Hotel, Imperial Ballroom
Webcast:     http://wsw.com/webcast/jeff105/gemp

About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH.  We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors.  Gemphire has 3 clinical trials ongoing for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH in second half of 2017.  Please visit www.gemphire.com for more information.

Contact:

Andrew McDonald, Ph.D.
LifeSci Advisors, LLC
(646) 597-6987

Jeff Mathiesen, CFO
Gemphire Therapeutics Inc.
(734)-245-1700

Primary Logo

Gemphire Therapeutics